Evidence map›Paper›PMID 31011161›Full record

ArticleScientific reports2019

Design and synthesis of anticancer 1-hydroxynaphthalene-2-carboxanilides with a p53 independent mechanism of action.

Ewelina Spaczyńska, Anna Mrozek-Wilczkiewicz, Katarzyna Malarz, Jiri Kos, Tomas Gonec, Michal Oravec, Robert Gawecki, Andrzej Bak, Jana Dohanosova, Iva Kapustikova and 3 more

Abstract read
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Salicylanilides and Their Anticancer Properties.International journal of molecular sciences · 2023
    Review
  5. Article
  6. IRSC advances · 2022
    Article
  7. Article
  8. Consensus-Based Pharmacophore Mapping for New Set ofInternational journal of molecular sciences · 2020
    Article
  9. Article
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Ewelina SpaczyńskaInstitute of Chemistry, University of Silesia, 75 Pułku Piechoty 1a, 41-500, Chorzów, Poland.
Anna Mrozek-WilczkiewiczA. Chełkowski Institute of Physics and Silesian Center for Education and Interdisciplinary Research, University of Silesia, 75 Pułku Piechoty 1a, 41-500, Chorzów, Poland.
Katarzyna MalarzA. Chełkowski Institute of Physics and Silesian Center for Education and Interdisciplinary Research, University of Silesia, 75 Pułku Piechoty 1a, 41-500, Chorzów, Poland.ORCID http://orcid.org/0000-0003-4283-3126
Jiri KosDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Comenius University, Odbojarov 10, 832 32, Bratislava, Slovakia.
Tomas GonecDepartment of Chemical Drugs, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences, Palackeho 1, Brno, 612 42, Czech Republic.
Michal OravecGlobal Change Research Institute CAS, Belidla 986/4a, Brno, 603 00, Czech Republic.
Robert GaweckiA. Chełkowski Institute of Physics and Silesian Center for Education and Interdisciplinary Research, University of Silesia, 75 Pułku Piechoty 1a, 41-500, Chorzów, Poland.
Andrzej BakInstitute of Chemistry, University of Silesia, 75 Pułku Piechoty 1a, 41-500, Chorzów, Poland.
Jana DohanosovaCentral Laboratories, Faculty of Chemical and Food Technology, Slovak University of Technology in Bratislava, Radlinskeho 9, Bratislava, 81237, Slovakia.
Iva KapustikovaDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Comenius University, Odbojarov 10, 832 32, Bratislava, Slovakia.
Tibor LiptajCentral Laboratories, Faculty of Chemical and Food Technology, Slovak University of Technology in Bratislava, Radlinskeho 9, Bratislava, 81237, Slovakia.
Josef JampilekDepartment of Analytical Chemistry, Faculty of Natural Sciences, Comenius University, Ilkovicova 6, 842 15, Bratislava, Slovakia. josef.jampilek@gmail.com.ORCID http://orcid.org/0000-0003-2003-9052
Robert MusiolInstitute of Chemistry, University of Silesia, 75 Pułku Piechoty 1a, 41-500, Chorzów, Poland. robert.musiol@us.edu.pl.ORCID http://orcid.org/0000-0002-6219-7369

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A series of 116 small-molecule 1-hydroxynaphthalene-2-carboxanilides was designed based on the fragment-based approach and was synthesized according to the microwave-assisted protocol. The biological activity of all of the compounds was tested on human colon carcinoma cell lines including a deleted TP53 tumor suppressor gene. The mechanism of activity was studied according to the p53 status in the cell. Several compounds revealed a good to excellent activity that was similar to or better than the standard anticancer drugs. Some of these appeared to be more active against the p53 null cells than their wild-type counterparts. Intercalating the properties of these compounds could be responsible for their mechanism of action.

Indexed as

Drug DesignAntineoplastic AgentsApoptosisCell ProliferationDNADoxorubicinHCT116 CellsHumansIntercalating AgentsModels, MolecularNaphtholsSmall Molecule LibrariesTumor Suppressor Protein p531-naphtholAntineoplastic Agentscalf thymus DNADNADoxorubicinIntercalating AgentsNaphtholsSmall Molecule LibrariesTumor Suppressor Protein p53

Identifiers

PMID31011161
PMCPMC6476888

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.